While it's far too early to begin talking about a phoenix-like resurgence, Johnson & Johnson shows initial signs of at least shaking up what in recent years has become a far too comfortably stratified coronary stent market. This after J&J's Cordis Corp. received FDA approval of its new Bx Velocity stent in mid-May, several weeks earlier than anticipated.
It used to be that the stent market could be relied on to periodically produce dramatic Nasdaq-like shifts in market...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?